A Phase 1 interventional study of mRNA-1010 and mRNA-1345 in SARS-CoV-2, Influenza and RSV, sponsored by ModernaTX, Inc.. Completed at 30 sites in 3 countries. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-08.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 7th largest by enrollment, is one of 6 that started in 2022, is one of 3 in phase 1, and was the 6th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2021; this study’s year is marked. 6 started in 2022.
This study's enrollment of 392 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 471 across the 12 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
23 studies in Influenza, Human by Moderna, Inc.: 2 open now, 3 under way, 1 of them phase 3. Of 20 finished, 12 (60%) have results posted.
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 16th largest by enrollment, is one of 7 that started in 2022, is one of 5 in phase 1, and was the 9th registered.
Moderna, Inc.’s Influenza, Human studies by the year they started, since 2015.
1 of the studies testing mRNA-1010 influenza vaccine in Influenza, Human that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, from their registry updates:
Among Moderna, Inc.’s 23 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
Biological: mRNA-1010
Participants will receive a dose of mRNA-1345 by IM injection on Day 1.
Biological: mRNA-1345
Participants will receive a dose of mRNA-1273.214 by IM injection on Day 1.
Biological: mRNA-1273.214
Participants will receive mRNA-1045 at Dose Level A by IM injection on Day 1.
Biological: mRNA-1045
Participants will receive mRNA-1045 at Dose Level B by IM injection on Day 1.
Biological: mRNA-1045
Participants will receive mRNA-1045 at Dose Level C by IM injection on Day 1.
Biological: mRNA-1045
Participants will receive mRNA-1230 at Dose Level A by IM injection on Day 1.
Biological: mRNA-1230
Participants will receive mRNA-1230 at Dose Level B by IM injection on Day 1.
Biological: mRNA-1230
Participants will receive mRNA-1230 at Dose Level C by IM injection on Day 1.
Biological: mRNA-1230
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Formulation for injection
Formulation for injection
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time frame: Up to Day 8 (7 days post vaccination)
Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Up to Day 29 (28 days post vaccination)
Number of Participants with Medically-Attended AEs (MAAEs)
Time frame: Day 1 through Day 361
Number of Participants with Adverse Events of Special Interest (AESIs)
Time frame: Day 1 through Day 361
Number of Participants with Serious Adverse Events (SAEs)
Time frame: Day 1 through Day 361
Number of Participants with AEs Leading to Discontinuation
Time frame: Day 1 through Day 361
Change From Baseline in Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay at Day 29
Time frame: Baseline (Day 1), Day 29
Change From Baseline in GMT as Measured by Pseudovirus Neutralization Assay (PsVNA) (or Binding Antibody Assay) at Day 29
Time frame: Baseline (Day 1), Day 29
Change From Baseline in GMT as Measured by Microneutralization Assay at Day 29
Time frame: Baseline (Day 1), Day 29
Change From Baseline in Geometric Mean Fold-Rise (GMFR) as Measured by HAI Assay at Day 29
Time frame: Baseline (Day 1), Day 29
Change From Baseline in GMFR as Measured by PsVNA (or Binding Antibody Assay) at Day 29
Time frame: Baseline (Day 1), Day 29
Change From Baseline in GMFR as Measured by Microneutralization Assay at Day 29
Time frame: Baseline (Day 1), Day 29
Influenza: Percentage of Participants with Seroconversion as Measured by HAI Assay
Seroconversion is defined as a Day 29 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay.
Time frame: Baseline (Day 1) to Day 29
SARS-CoV-2: Percentage of Participants with Seroresponse as Measured by PsVNA (or Binding Antibody Assay)
Seroresponse is defined as a Day 29 titer ≥4-fold if baseline is ≥lower limit of quantification (LLOQ) or ≥4\*LLOQ if baseline titer is \<LLOQ in nAb titers measured by PsVNA (or binding antibody assay).
Time frame: Baseline (Day 1) to Day 29
RSV: Percentage of Participants with Seroresponse as Measured by RSV Neutralization Assay
Seroresponse is defined as a Day 29 titer ≥4-fold if baseline is ≥LLOQ or ≥4\*LLOQ if baseline titer is \<LLOQ in nAb titers measured by RSV neutralization assay.
Time frame: Baseline (Day 1) to Day 29
Ran from Oct 2022 to primary completion in Feb 2024, 16 months.
Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 16 months is above that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: mRNA-1010 influenza vaccine · mRNA-1345 respiratory syncytial virus vaccine · mRNA-1273.214 COVID-19 vaccine